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ABSTRACT
Nowadays, one of the modalities in performing reperfusion in coronary artery disease is
percutaneous coronary intervention. Before drug eluting stent era, the problem that occurs the
most among interventional cardiologists is restenosis. After drug eluting stent era, restenosis
can be reduced significantly. Unfortunately, it further develops another problem, that is called
stent thrombosis. Mechanism of stent thrombosis is related to vascular response, thrombosis,
coagulation, and clinical factors. Based on our experience, non-ST elevation acute myocardial
infarction is caused by probable acute stent thrombosis after drug eluting stent implantation.
Therefore, the prevention and therapeutic approaches should be put first in our priority because
it can provide a serious complication.
ABSTRAK
Saat ini, satu modalitas untuk melakukan reperfusi penyakit jantung koroner adalah intervensi
koroner perkutan. Sebelum zaman sten berlumur obat, masalah yang paling sering dihadapi
dokter jantung intervensi adalah kejadian restenosis. Setelah zaman sten berlumur obat, restenosis
dapat diturunkan secara signifikan. Sayangnya, kemudian timbul masalah lain yang disebut
dengan trombosis sten. Mekanisme trombosis sten berkaitan dengan respon pembuluh darah,
trombosis, koagulasi, dan faktor klinis. Kami laporkan pengalaman kami dengan non-ST elevasi
infark miokard akut yang disebabkan oleh trombosis sten akut (probable) setelah implantasi sten
berlumur obat. Maka dari itu, pencegahan dan pendekatan terapi terhadap masalah ini harus
menyadarkan kita, karena dapat menimbulkan komplikasi yang serius.
Keywords : coronary artery disease - percutaneous coronary intervention – drug eluting stent -
stent thrombosis - acute coronary syndrome
INTRODUCTION
Restenosis is a weakness of coronary artery
stent implantation. The discovery of drug eluting
stents (DES) has been able to reduce the
incidence of restenosis dramatically. Recently,
studies have shown that a decrease in the
incidence of restenosis is often followed by a
higher incidence of stent thrombosis, especially
late stent thrombosis.1
The incidence of stent thrombosis has been
reported in several studies, ranging between 0.5
- 2%. Although the incidence is not high, stent
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thrombosis has major clinical effects due to its
high risk of myocardial infarction and death.
The mortality rate caused by stent thrombosis
is relatively high—approximately 45%.2
The standard definition of stent thrombosis
according to the Academic Research Consor-
tium (ARC) based on the level of documentation
are: 1) definite or confirmed (symptoms
suggestive of acute coronary syndrome and
angiography or pathological confirmation of
stent thrombosis), 2) probable (deaths that
cannot be explained in 30 days or myocardial
infarction without confirmation of stent
thrombosis in the target blood vessel
angiographically), 3) possible (any unexplained
death after 30 days). Meanwhile, based on the
time since stent implantation, stent thrombosis
can be classified as: 1) early (0 - 30 days after
stent implantation), 2) late (> 30 days), 3) very
late (> 12 months). Early stent thrombosis is
often divided into acute (<24 hours) and sub-
acute (> 24 hours-30 days).3
Based on our experience, it is reported that
non-ST elevation acute myocardial infarction
(NSTEMI) is caused by probable acute stent
thrombosis after implantation DES in patients
with stable angina pectoris.
CASE REPORT
A 48-year-old male came with stable angina
pectoris Canadian Classifications Cardiology
Society (CCS) class 2-3 to be performed PCI.
Blood tests showed normal limits. The result
of the electrocardiographic (ECG) resting
showed sinus rhythm and no ST-T changes
(FIGURE 1). Chest x-ray showed that the heart
and lungs were in the normal range.
Transthoracic echocardiography found normal
cardiac chamber dimensions, global left
ventricular systolic function within the normal
range with an ejection fraction of 55%, mild
hypokinetic apical, diastolic dysfunction type
of relaxation, normal right ventricular systolic
function, and normal valves.
FIGURE 1. ECG recordings at the time of admission showed sinus
rhythm and no ST-T changes
Coronary angiography showed normal left
main, stenosis of 80% of the length from the
proximal to mid left anterior descendent (LAD),
a big left circumflex (LCX) despite that there
was a 60% stenosis in the mid after obtuse
marginal 1 (FIGURE 2). Right CoronaryArtery
(RCA) stenosis 70-75% in the mid and 60% in
the distal before the bifurcation (FIGURE 3).
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FIGURE 2. A. stenosis of 80% of the length from the proximal to mid LAD, LCX was big but there was a 60%
stenosis in the mid after obtuse marginal 1, B. LAD after stent was implanted
FIGURE 3. A. RCA stenosis 70-75% in the mid and 60% in the distal before the bifurcation, B. RCA after stent
implantation
Stent implantation was performed with the
target LAD and RCA lesions using drug eluting
stents (DES). Shortly after being treated in the
Intermediate Cardiovascular Care (IMCC), the
patient complained of chest pain, spreading to
the left arm, which was not accompanied by a
cold sweat. His vital sign was within normal
limits. The patient was given tablets isosorbide
dinitrate (ISDN) at dose of 5 mg sublingual.
Five minutes later the patient still complained
of chest pain, and it was then decided to give
him intravenous injection of 2 mg morphine.
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Electrocardiograph recordings showed sinus
rhythm with slight ST elevation and T wave
inversion in leads V2-V3, different with the
ECG prior to the procedure (FIGURE 4).
Creatin kinase isoenzym MB (CKMB) and
Troponin I levels increased respectively 30 and
0.9. Patient was diagnosed as probable acute
stent thrombosis and moved to ICCU for more
intensive care. FIGURE 5 shows the ECG when
the patient was discharged.
FIGURE 4. Electrocardiograph recordings showed sinus
rhythm with slight ST elevation and T wave
inversion in leads V2-V3
FIGURE 5. Figure 5 shows the ECG when the patient was
discharged. No more ST-T changes in leads
V2-V3
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DISCUSSION
In two decades, coronary artery stent has
been introduced to clinical practice with 2
goals, namely to prevent the incidence of
restenosis in one hand and treat the sudden
blockage of blood vessels on the other hand.
Stent implantation has increased dramatically
until a new problem appears, namely stent
thrombosis.Aggressive antithrombotic regimens
were then introduced. Aspirin is administered
with dipyridamole, sulfapyrazone, and oral
anticoagulants (acenocoumarin) up to 6 months.
However, the incidence of stent thrombosis is
still quite high, ranging from 6% -12%.4
Pathophysiology of stent thrombosis
includes factors related to the stent, the
procedure and the patient (TABLE 1). Stent
thrombosis can occur either with a bare metal
stent (BMS) or DES. Incidence of immediate
(early) thrombosis may be associated with
thrombus or dissection at the target lesion,
stasis, less stent expansion or a combination of
all.5
TABLE 1. Factors which cause stent thrombosis6
Analogous to the BMS era, early stent
thrombosis with DES shows an increased risk
based on clinical settings, from low risk patients
with stable coronary artery disease,
intermediate patients with non-ST acute
coronary syndrome to high risk patients with
ST elevation myocardial inarction STEMI
(TABLE 2).
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TABLE 2. Early stent thrombosis risk based on clinical presentation4
The most important risk factor for acute and
sub-acute stent thrombosis is the primary stent
in STEMI and acute coronary syndrome.
Additional risk factor is the length of the stent,
congestive heart failure and prothrombogenic
status, such as metastatic cancer.7
BMS and DES induce platelet adhesion,
activation and thrombus formation. Stent
gradually covered by endothelial cells does not
induce thrombus formation. Cytotoxic drugs are
used in the DES to reduce the growth of smooth
muscle cells after coronary intervention endo-
thel-alization to inhibit this process. Sirolimus
and paclitaxel induce the expression of tissue
factor on the mounted stent lesions that cause
activation of the coagulation system. Polymers
are used to release these drugs to cause
inflammation of the coronary artery shown by
the infiltration of eosinophilia cells in the blood
vessel wall which is suggestive to a hyper-
sensitivity reaction, and this also contributes to
the prothrombotic environment.7
Ten to thirty percents patients with definite
stent thrombosis will die in the hospital. In
addition, non-fatal acute myocardial infarction
is the most common clinical presentation of stent
thrombosis (70-80% of cases).8
The main objective of the management of
stent thrombosis is to achieve effective
reperfusion immediately. Type of thrombus in
patients with stent thrombosis is different to that
of the ordinary acute myocardial infarction
patients. Thrombus on stent thrombosis is almost
entirely composed of very few platelets and
fibrin. As this can lead to an ineffective
thrombolysis for reperfusion, most authors
advised emergency PCI for treatment of stent
thrombosis.9
The introduction of dual antiplatelet therapy
with aspirin and a thienopyridine ticlopidine,
and shift indication of stent implantation forms
bailout to elective case procedures, resulting
in a significant reduction of stent thrombosis to
<2%, as well as fewer bleeding complications.
Attention to the importance of stent implantation
technique, proper medication before the
procedure and loading with thienopyridine, and
the use of antagonists glycoprotein IIb/ IIIa in
the setting of acute coronary syndrome results
in more decreased stent thrombosis cases.10
Several studies have demonstrated the
advantages of dual antiplatelet therapy of aspirin
plus ticlopidine on early and clopidogrel plus
aspirin in the first 4 weeks after BMS
implantation. The combination of aspirin and
clopidogrel is more widely used because it has
fewer side effects. Since the introduction of
DES, the result shows that this therapy should
be continued for 3-6 months. Recent guidelines
recommend dual antiplatelet therapy 12 months
after implantation of DES. Some authors suggest
that this therapy should be continued until more
than 12 months but there is no data available to
support the safety and benefits of this
combination.9
The basis of the prevention of stent
thrombosis is doing the best PCI procedures,
including good stent expansion and apposition.
In this context, the role of intravascular
ultrasound should be considered. The role of
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antiplatelet therapy in the prevention of early
stent thrombosisis is already well known.11
Several studies have shown the benefits of
clopidogrel loading dose. In the setting of acute
coronary syndrome, it should be given 600 mg
loading dose. Even Montalescot et al.12
recommends that 900 mg loading dose of
clopidogrel can improve platelet inhibition.
TRITON TIMI-38 study showed inhibition of
platelet aggregation with prasugrel better than
standard therapy with clopidogrel and lowering
the incidence of stent thrombosis significantly.
However, a higher incidence of major bleeding
still shows a lack of systematic prescribing
prasugrel, so it is not recommended for routine
practice.9
Several risk factors for the occurrence of
stent thrombosis were found in these patients,
namely kidney failure and malignancy. Patients’
creatinine level was 2.13 and these patients had
a history of lung carcinoma. Both of these
factors lead to a higher prothrombogenic status.
The results of coronary angiography showed a
long lesion in LAD which increases the risk of
stent thrombosis. ECG recording after the
procedure showed ST segment changes in leads
V2-V4, according to the LAD vascularization.
The presence of these risk factors may explain
why patients had a stable clinical setting at first
and then suffered stent thrombosis after DES
implantation. The clinical presentation of stent
thrombosis in these patients was non-fatal acute
myocardial infarction, which is most often the
case.
Working diagnosis of these patients was
probable acute stent thrombosis, with the
clinical presentation of acute myocardial
infarction as evidenced by typical chest pain,
ST segment changes on ECG dynamic and rising
levels of cardiac enzymes. Management of these
patients is similar as NSTEMI management in
general: being given aspirin and clopidogrel
loading dose, continuing with dual antiplatelet
therapy, beta receptor blockers and heparin. In
these patients percutaneous coronary
intervention had not been done, because there
was no ST elevation. After being treated for 3
days in ICCU, the patients were allowed to go
home.
CONCLUSION
A case of NSTEMI caused by probable
acute stent thrombosis after percutaneous
coronary intervention has been reported. There
are some risk factors found associated with the
stent thrombosis, i.e. elevated levels of
creatinine, prothrombogenic status because of
a history of lung malignancy and the presence
of long lesions in LAD.Although the incidence
of stent thrombosis was low, it should be paid
attention quickly because mortality and the
incidence of acute myocardial infarction are
high. Handling thrombosis at the beginning is
very important, as to prevent the incidence of
stent thrombosis in patients with stent
implantation, although the clinical presentation
shows a low risk for thrombosis.
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